Cargando…
Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum of diseases from simple steatosis to non-alcoholic steatohepatitis, with approximately 20% risk of progressing to fibrosis and cirrhosis. The aim of this study was to compare the relative expression levels of circulating miR-21, miR-34a, mi...
Autores principales: | Salvoza, Noel C., Klinzing, David C., Gopez-Cervantes, Juliet, Baclig, Michael O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831793/ https://www.ncbi.nlm.nih.gov/pubmed/27077736 http://dx.doi.org/10.1371/journal.pone.0153497 |
Ejemplares similares
-
Microvesicle-associated and circulating microRNAs in diabetic dyslipidemia: miR-218, miR-132, miR-143, and miR-21, miR-122, miR-155 have biomarker potential
por: Nemecz, Miruna, et al.
Publicado: (2023) -
Circulating microRNAs (miR‐16, miR‐22, miR‐122) expression and early diagnosis of hepatocellular carcinoma
por: Fang, Yujia, et al.
Publicado: (2022) -
MiR-223-3p and miR-122-5p as circulating biomarkers for plaque instability
por: Singh, Sandeep, et al.
Publicado: (2020) -
Serum levels of miR-29, miR-122, miR-155 and miR-192 are elevated in patients with cholangiocarcinoma
por: Loosen, Sven H., et al.
Publicado: (2019) -
Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors
por: Israelow, Benjamin, et al.
Publicado: (2014)